+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Low Molecular Weight Heparin"

Low Molecular Weight Heparin Global Market Report 2024 - Product Thumbnail Image

Low Molecular Weight Heparin Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
From
Heparin - Global Strategic Business Report - Product Thumbnail Image

Heparin - Global Strategic Business Report

  • Report
  • March 2025
  • 184 Pages
  • Global
From
Fondaparinux - Global Strategic Business Report - Product Thumbnail Image

Fondaparinux - Global Strategic Business Report

  • Report
  • March 2025
  • 93 Pages
  • Global
From
Anticoagulants - Global Strategic Business Report - Product Thumbnail Image

Anticoagulants - Global Strategic Business Report

  • Report
  • March 2025
  • 196 Pages
  • Global
From
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025 - Product Thumbnail Image

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Heparin Market Report 2025 - Product Thumbnail Image

Heparin Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Thumbnail Image

Anticoagulants Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
From
From
Anticoagulants Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Anticoagulants Market - Forecasts from 2025 to 2030

  • Report
  • January 2025
  • 144 Pages
  • Global
From
From
From
From
Global Heparin Market Outlook 2030 - Product Thumbnail Image

Global Heparin Market Outlook 2030

  • Report
  • October 2021
  • 154 Pages
  • Global
From
Loading Indicator

Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases. The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome. Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more